Gentris Corporation To Exclusively Market Its FDA-Approved Human Genomic Reference Controls

Gentris Corporation (Gentris) today announced FDA clearance for GentriSure™, its first product line and the first FDA-cleared product for this specialty pharmacogenomics company. These six Human Genomic Reference Controls, the first products of their kind approved by a federal agency, are used to perform diagnostic testing for the Cytochrome P450 2D6 gene (CYP2D6). Gentris, a leading global provider of applied clinical pharmacogenomic services and diagnostic product solutions, can now add FDA approval and a GMP-compliant device manufacturer to its long list of accomplishments.